NDAINTRAMUSCULARFOR SUSPENSION, EXTENDED RELEASE
Approved
Jan 2023
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
20
Data completeness
3/8 — Basic
Drug data last refreshed 18h ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
RYKINDO is an extended-release intramuscular suspension formulation of risperidone, a second-generation antipsychotic approved in January 2023. It is indicated for schizophrenia and bipolar disorder, with the long-acting injection designed to improve medication adherence in patients requiring maintenance antipsychotic therapy. Risperidone works as a dopamine and serotonin antagonist to reduce psychotic and mood symptoms.
Peak5.4 years to LOE
Recently approved product in peak lifecycle phase with no identified direct competitors, indicating potential for market share growth and expanded commercial team hiring.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (20)
Safety, Tolerability, and Pharmacokinetics of Switching From Oral Risperidone to Risperidone Implant
Started Apr 2021
34 enrolled
Schizophrenia
Safety, Tolerability, Pharmacokinetics and Efficacy of 180 mg Subcutaneous Risperidone From 6 mg Oral Risperidone
Started Jun 2019
69 enrolled
Schizophrenia
A Study to Evaluate the Ability of Conducting a Study of Oral Risperidone Followed by Paliperidone Palmitate in Rwandan Healthcare Facilities
Started Oct 2018
34 enrolled
Schizophrenia
Mirror-image Study of Paliperidone Palmitate and Risperidone Long-acting Injection
Started Jan 2018
328 enrolled
Schizophrenia Spectrum and Other Psychotic Disorders
Comparison of the Effectiveness of Brexpiprazole With That of Risperidone
Started Jun 2016
0Schizophrenia
Worked on RYKINDO at Luye Pharma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.